Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation : findings from the GARFIELD-AF registry

Tools
- Tools
+ Tools

Apenteng, Patricia N., Gao, Haiyan, Hobbs, Richard and Fitzmaurice, David A. (2018) Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation : findings from the GARFIELD-AF registry. BMJ Open, 8 . e018905. doi:10.1136/bmjopen-2017-018905 ISSN 2044-6055.

[img]
Preview
PDF
WRAP-temporal-trends-antithrombotic-treatment-patients-atrial-registry-Apenteng-2018.pdf - Published Version - Requires a PDF viewer.
Available under License Creative Commons: Attribution-Noncommercial 4.0.

Download (1016Kb) | Preview
[img] Microsoft Word
WRAP-wms_clinical_trials-101117-wrap--garfield_uk_treatment_patterns_paper_bmj_open_authors_version.docx - Accepted Version
Embargoed item. Restricted access to Repository staff only

Download (84Kb)
[img] Microsoft Word
wms_clinical_trials-101117-wrap--table_1._baseline_characteristics_of_patients_in_cohorts_2_to_5.docx - Supplemental Material
Embargoed item. Restricted access to Repository staff only

Download (21Kb)
[img] Microsoft Word
wms_clinical_trials-101117-wrap--table_3._baseline_characteristics_of_patients_on_noacs_by_cohort.docx - Supplemental Material
Embargoed item. Restricted access to Repository staff only

Download (18Kb)
[img] Microsoft Word
wms_clinical_trials-101117-wrap--table_2._baseline_characteristics_of_patients_in_cohort_2_to_5_by_antithrombotic_treatment_type.docx - Supplemental Material
Embargoed item. Restricted access to Repository staff only

Download (20Kb)
Official URL: http://dx.doi.org/10.1136/bmjopen-2017-018905

Request Changes to record.

Abstract

Objective

To investigate evolving patterns in antithrombotic treatment in UK patients with newly diagnosed non-valvular atrial fibrillation (AF).

Design

Prospective, multicentre, international registry.

Setting

186 primary care practices in the UK.

Participants

3482 participants prospectively enrolled in four sequential cohorts (cohort 2 (C2) n=830, diagnosed September 2011 to April 2013; cohort 3 (C3) n=902, diagnosed April 2013 to June 2014; cohort 4 (C4) n=850, diagnosed July 2014 to June 2015; cohort 5 (C5) n=900, diagnosed June 2015 to July 2016). Participants had newly diagnosed non-valvular AF and at least one risk factor for stroke, were aged ≥18, and provided informed consent.

Main outcome measures

Antithrombotic treatment initiated at diagnosis, overall and according to stroke and bleeding risks. Stroke risk was retrospectively calculated using CHA2DS2-VASc (cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)–vascular disease, age 65–74 and sex category (female)) and bleeding risk using HAS-BLED (hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, elderly (>65), drugs/alcohol concomitantly (1 point each)).

Results

42.7% were women and the mean age was 74.5 years. The median CHA2DS2-VASc score was 3 in all cohorts and the median HAS-BLED score was 2 in all cohorts. There was a statistically significant increase in the use of anticoagulant therapy from C2 to C5 (C2 54.7%, C3 60.3%, C4 73.1%, C5 73.9%; P value for trend <0.0001). The increase in the use of anticoagulant was mainly in patients with CHA2DS2-VASc ≥2. The use of vitamin K antagonists (VKAs)±antiplatelet (AP) drugs decreased from C2 to C5 (C2 53.3%, C3 52.1%, C4 50.3%, C5 30.6%), while the use of non-vitamin K antagonist oral anticoagulants (NOACs)±AP increased (C2 1.3%, C3 8.0%, C4 22.7%, C5 43.3%). The use of AP only decreased (C2 36.4%, C3 25.5%, C4 11.9%, C5 10.5%), as did the combination therapy of VKA+AP (C2 13.6%, C3 11.0%, C4 9.6%, C5 5.8%).

Conclusion

There has been a progressive increase in the proportion of patients newly diagnosed with AF receiving guideline-recommended therapy in the UK, potentially driven by the availability of NOACs.

Item Type: Journal Article
Subjects: R Medicine > RC Internal medicine
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Clinical Trials Unit
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Atrial fibrillation -- Treatment, Atrial fibrillation -- Diagnosis
Journal or Publication Title: BMJ Open
Publisher: BMJ
ISSN: 2044-6055
Official Date: 13 January 2018
Dates:
DateEvent
13 January 2018Published
3 November 2017Accepted
Volume: 8
Article Number: e018905
DOI: 10.1136/bmjopen-2017-018905
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access (Creative Commons)
Date of first compliant deposit: 14 November 2017
Date of first compliant Open Access: 2 May 2018
RIOXX Funder/Project Grant:
Project/Grant IDRIOXX Funder NameFunder ID
UNSPECIFIEDNational Institute for Health Researchhttp://dx.doi.org/10.13039/501100000272

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us